Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Novartis |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00354523 |
Primary objectives:
Secondary objectives:
1. To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination.
Condition | Intervention | Phase |
---|---|---|
Solid Tumor Thyroid Cancer |
Drug: Capecitabine Drug: Dacarbazine Drug: Imatinib |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma |
Estimated Enrollment: | 52 |
Study Start Date: | December 2004 |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
U.T. M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Alexandria T. Phan, MD | M.D. Anderson Cancer Center |
Study ID Numbers: | 2004-0475 |
Study First Received: | July 18, 2006 |
Last Updated: | July 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00354523 |
Health Authority: | United States: Food and Drug Administration |
Solid Tumor Thyroid Cancer Capecitabine Dacarbazine Imatinib |
Imatinib Capecitabine Dacarbazine Thyroid Neoplasms Head and Neck Neoplasms Thyroid cancer, medullary |
Endocrine System Diseases Endocrinopathy Thyroid Diseases Endocrine Gland Neoplasms Carcinoma |
Antimetabolites Neoplasms Antimetabolites, Antineoplastic Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Antineoplastic Agents, Alkylating Protein Kinase Inhibitors Alkylating Agents Pharmacologic Actions |